

**Remarks**

Claims 13, 14, 15, 17 and 19 are pending following this amendment. Claims 1-12, 16, 18 and 20-21 have been cancelled.

The amendment to Claim 13 brings the scope of Claim 13 into ambit with an exclusionary proviso submitted during the international stage of this application. Claims 17 and 19 have been amended to depend from Claim 13 rather than reference a compound of Formula I. In addition, Claim 17 has been limited to a method of treating obesity which is consistent with the disclosure. Applicants contend no new matter has been added by any amendment to the claims.

Applicants request favorable consideration of the presently claimed invention.

Respectfully submitted,



John C. Demeter  
Attorney for Applicants  
Registration No. 30,167  
Phone: 317-276-3785

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

April 11, 2006